ClinicalTrials.gg
CompletedNCT07643272Updated Sep 18, 2026

A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules

A Phase 1 interventional study of HMPL-760 and Rabeprazole and HMPL-760 in Healthy Participants, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants. The study consists of a screening period, a dosing period (Cycles 1, 2, 3, and 4), and a follow-up period. Screening must occur within 14 days prior to the first dose of study drug. Enrolled participants will be randomly assigned to one of 6 dosing sequences in the ratio of 1:1:1:1:1:1 to complete Cycles 1-3 dosing to evaluate the effect of different types of food on the PK of HMPL-760, and then to receive rabeprazole and HMPL-760 in Cycle 4 to assess the effect of PPI on the PK of HMPL-760 (see dosing sequence table for details).

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants are fully aware of this study and voluntarily sign the ICF.
  2. Male or female aged 18 to 45 years old (inclusive).
  3. Participant's (BMI) at screening: 18 kg/m2 \< BMI ≤ 29.9 kg/m2 and weight ≥ 50 kg for males and ≥ 45 kg for females.
  4. Participant is willing and able to comply with the protocol in all aspects.

Exclusion criteria

Exclusion Criteria:

  1. Known history of any gastrointestinal surgery or any condition that could affect drug absorption (e.g., cholecystectomy, achlorhydria, peptic ulcer disease, gastric/intestinal surgery or history of resection; prior appendectomy or hernia repair is allowed).
  2. disease within 8 weeks prior to the first dose or clinically significant infection within 4 weeks prior to the first dose.
  3. Clinically significant abnormal findings in physical examination, vital signs, or laboratory tests at screening.
  4. Systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at screening.
  5. Participants who smoked over 10 cigarettes daily within 3 months before screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A- HMPL-760

    All participants in treatment A will fast overnight for at least 10 hours prior to HMPL-760 dosing.

    Drug: HMPL-760

  • Experimental
    Treatment B- HMPL-760

    All participants in treatment B will receive a standardized high-fat meal approximately 30 minutes before HMPL-760 administration

    Drug: HMPL-760

  • Experimental
    Treatment C- HMPL-760

    All participants in treatment C will receive a standardized low-fat meal approximately 30 minutes before HMPL-760 administration

    Drug: HMPL-760

  • Experimental
    Treatment D- Rabeprazole and HMPL-760

    All participants receive rabeprazole 20 mg orally QD(Quaque Die) 1 h before the breakfast on Day 15 and the morning of Day 16 to Day 20. Rabeprazole and HMPL-760 are orally administered concomitantly under fasted conditions on the morning of Day 21.

    Drug: Rabeprazole and HMPL-760

Interventions

  • 300 mg HMPL-760 will be administered orally once daily on Day 1, Day 6 and Day 11.

  • DrugRabeprazole and HMPL-760

    Drug pages: Rabeprazole · BTK Inhibitor HMPL-760

    20 mg of rabeprazole will be administered orally once daily in the morning from Day 15 to Day 21, and a 300 mg oral dose of HMPL-760 will be administered concomitantly with rabeprazole on Day21.

06

What researchers measure

Primary outcomes

  1. AUC 0-last

    Area under the plasma concentration-time curve from time zero to the last time point t where the concentration could be accurately determined

    Time frame: Day 1 to Day 25

  2. AUC 0-inf

    Area under the plasma concentration-time curve from time 0 to infinity

    Time frame: Day 1 to Day 25

  3. Cmax

    Maximum plasma concentration

    Time frame: Day 1 to Day 25

Secondary outcomes

  1. Tmax

    Time to Cmax

    Time frame: Day 1 to Day 25

  2. tlag

    Lag Time

    Time frame: Day 1 to Day 25

  3. t1/2

    Terminal elimination half-life

    Time frame: Day 1 to Day 25

  4. Adverse events rate

    Number of participants with treatment-related adverse events as assessed by CTCAE v6.0

    Time frame: Day 1 to Day 32(±1 day)

  5. Laboratory tests

    Number of participants with abnormal laboratory tests results

    Time frame: Day 1 to Day 32(±1 day)

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, Shanghai Municipality 200031, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Jul 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 11, 2026
StartActual
Jun 30, 2026
Primary completionActual
Jul 31, 2026
CompletionActual
Aug 31, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07643272
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Jun 30, 2026
Primary completion
Jul 31, 2026
Completion
Aug 31, 2026
Last update
Sep 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BTK Inhibitor HMPL-760 · Rabeprazole

Start the discussion